Kenvue (NYSE:KVUE) Announces Quarterly Earnings Results

Kenvue (NYSE:KVUE) posted its quarterly earnings results on Monday. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01, Zacks reports. The firm had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.28 earnings per share. Kenvue updated its FY 2025 guidance to 1.000-1.050 EPS.

Kenvue Stock Up 12.6%

Kenvue stock opened at $16.18 on Tuesday. Kenvue has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The stock has a market cap of $31.06 billion, a PE ratio of 21.87, a price-to-earnings-growth ratio of 2.07 and a beta of 0.71. The firm’s 50-day simple moving average is $17.11 and its 200 day simple moving average is $20.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be issued a dividend of $0.2075 per share. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 5.1%. Kenvue’s payout ratio is 112.16%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Advisory Services Network LLC boosted its holdings in Kenvue by 2.0% during the second quarter. Advisory Services Network LLC now owns 49,807 shares of the company’s stock worth $1,068,000 after purchasing an additional 983 shares during the last quarter. Hayek Kallen Investment Management boosted its holdings in Kenvue by 8.6% during the second quarter. Hayek Kallen Investment Management now owns 32,910 shares of the company’s stock worth $689,000 after purchasing an additional 2,610 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Kenvue by 1.1% during the second quarter. Corient Private Wealth LLC now owns 413,042 shares of the company’s stock worth $8,647,000 after purchasing an additional 4,606 shares during the last quarter. Benjamin Edwards Inc. boosted its holdings in Kenvue by 12.6% during the second quarter. Benjamin Edwards Inc. now owns 42,967 shares of the company’s stock worth $899,000 after purchasing an additional 4,799 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S boosted its holdings in Kenvue by 10.4% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 77,720 shares of the company’s stock worth $1,627,000 after purchasing an additional 7,345 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research report on Tuesday, October 14th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on shares of Kenvue in a research report on Friday, October 24th. Canaccord Genuity Group reissued a “hold” rating and set a $15.00 target price (down from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Finally, Citigroup decreased their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $20.17.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.